Safety of Psychotropic Medications in Pregnancy
Author Information
Author(s): Fabiano Nicholas, Wong Stanley, Gupta Arnav, Tran Jason, Bhambra Nishaant, Min Kevin K., Dragioti Elena, Barbui Corrado, Fiedorowicz Jess G., Gosling Corentin J., Cortese Samuele, Gandhi Jasmine, Saraf Gayatri, Shorr Risa, Vigod Simone N., Frey Benicio N., Delorme Richard, Solmi Marco
Primary Institution: University of Ottawa
Hypothesis
What are the associations between psychotropic medication use in pregnant individuals with mental disorders and adverse health outcomes?
Conclusion
The review found suggestive evidence of some adverse health outcomes associated with psychotropic medication use during pregnancy, but no convincing or highly suggestive evidence.
Supporting Evidence
- Evidence was suggestive for preterm birth in pregnant people with mental disorders receiving antidepressants.
- Small for gestational age was associated with pregnant people with depression receiving SSRIs.
- Major congenital malformations were linked to paroxetine use in the first trimester.
Takeaway
This study looked at how taking certain medications during pregnancy might affect both the mother and the baby. It found some possible risks, but nothing was certain.
Methodology
The study systematically reviewed and analyzed observational studies and meta-analyses regarding psychotropic medication use in pregnancy.
Potential Biases
Potential confounding by indication and severity of mental disorders were not fully accounted for in the included studies.
Limitations
The review did not include randomized controlled trials and focused on observational studies, which may have confounding factors.
Participant Demographics
The review included studies involving pregnant individuals with mental disorders.
Statistical Information
P-Value
p<0.05
Confidence Interval
1.24–2.12
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website